Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Coding of glioblastoma progression and therapy resistance through long noncoding RNAs
ID
Zottel, Alja
(
Author
),
ID
Šamec, Neja
(
Author
),
ID
Videtič Paska, Alja
(
Author
),
ID
Jovchevska, Ivana
(
Author
)
PDF - Presentation file,
Download
(1,40 MB)
MD5: 579F23183B4293F463D342D164FCAB4C
URL - Source URL, Visit
https://www.mdpi.com/2072-6694/12/7/1842
Image galllery
Abstract
Glioblastoma is the most aggressive and lethal primary brain malignancy, with an average patient survival from diagnosis of 14 months. Glioblastoma also usually progresses as a more invasive phenotype after initial treatment. A major step forward in our understanding of the nature of glioblastoma was achieved with large-scale expression analysis. However, due to genomic complexity and heterogeneity, transcriptomics alone is not enough to define the glioblastoma "fingerprint", so epigenetic mechanisms are being examined, including the noncoding genome. On the basis of their tissue specificity, long noncoding RNAs (lncRNAs) are being explored as new diagnostic and therapeutic targets. In addition, growing evidence indicates that lncRNAs have various roles in resistance to glioblastoma therapies (e.g., MALAT1, H19) and in glioblastoma progression (e.g., CRNDE, HOTAIRM1, ASLNC22381, ASLNC20819). Investigations have also focused on the prognostic value of lncRNAs, as well as the definition of the molecular signatures of glioma, to provide more precise tumor classification. This review discusses the potential that lncRNAs hold for the development of novel diagnostic and, hopefully, therapeutic targets that can contribute to prolonged survival and improved quality of life for patients with glioblastoma.
Language:
English
Keywords:
glioblastoma
,
brain cancer
,
noncoding genome
,
biomarker
,
prognosis
Work type:
Article
Typology:
1.02 - Review Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2020
Number of pages:
22 str.
Numbering:
Vol. 12, iss. 7, art. 1842
PID:
20.500.12556/RUL-128766
UDC:
616-006
ISSN on article:
2072-6694
DOI:
10.3390/cancers12071842
COBISS.SI-ID:
22155779
Publication date in RUL:
28.07.2021
Views:
1100
Downloads:
175
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Cancers
Shortened title:
Cancers
Publisher:
MDPI
ISSN:
2072-6694
COBISS.SI-ID:
517914137
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:
08.07.2020
Secondary language
Language:
Slovenian
Keywords:
glioblastom
,
možganski rak
,
nekodirani genom
,
biološki označevalec
,
prognoza
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
P1-0390
Name:
Funkcijska genomika in biotehnologija za zdravje
Funder:
ARRS - Slovenian Research Agency
Funding programme:
Young Researcher Grant
Funder:
ARRS - Slovenian Research Agency
Project number:
Z3-1869
Name:
Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic
Funder:
EC - European Commission
Funding programme:
Interreg
Project number:
146
Acronym:
TRANS-GLIOMA
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back